Your browser doesn't support javascript.
loading
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Iida, Shinsuke; Wakabayashi, Masashi; Tsukasaki, Kunihiro; Miyamoto, Kenichi; Maruyama, Dai; Yamamoto, Kazuhito; Takatsuka, Yoshifusa; Kusumoto, Shigeru; Kuroda, Junya; Ando, Kiyoshi; Kikukawa, Yoshitaka; Masaki, Yasufumi; Kobayashi, Miki; Hanamura, Ichiro; Asai, Hiroaki; Nagai, Hirokazu; Shimada, Kazuyuki; Tsukamoto, Norifumi; Inoue, Yoshiko; Tobinai, Kensei.
Afiliação
  • Iida S; Department of Hematology and Oncology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Nagoya City University Hospital, Nagoya, Japan.
  • Wakabayashi M; JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
  • Tsukasaki K; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Cancer Center Hospital East, Kashiwa, Japan.
  • Miyamoto K; JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan.
  • Maruyama D; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Cancer Center Hospital, Tokyo, Japan.
  • Yamamoto K; Department of Hematology and Cell Therapy, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Aichi Cancer Center Hospital, Nagoya, Japan.
  • Takatsuka Y; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Imamura General Hospital, Kagoshima, Japan.
  • Kusumoto S; Department of Hematology and Oncology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Nagoya City University Hospital, Nagoya, Japan.
  • Kuroda J; Division of Hematology and Oncology, Department of Medicine, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Kyoto Prefectural University, Kyoto, Japan.
  • Ando K; Department of Hematology and Oncology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Tokai University of School of Medicine, Isehara, Japan.
  • Kikukawa Y; Department of Hematology, Rheumatology and Infectious Diseases, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Kumamoto University Hospital, Kumamoto, Japan.
  • Masaki Y; Department of Hematology and Immunology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Kanazawa Medical University, Kahoku, Japan.
  • Kobayashi M; Department of Hematology and Oncology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
  • Hanamura I; Division of Hematology, Department of Internal Medicine, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Aichi Medical University, Nagakute, Japan.
  • Asai H; First Department of Internal Medicine, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Ehime University Hospital, Toon, Japan.
  • Nagai H; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Shimada K; Department of Hematology and Oncology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Tsukamoto N; Oncology Center, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), Gunma University Hospital, Maebashi, Japan.
  • Inoue Y; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
  • Tobinai K; Department of Hematology, Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG), National Cancer Center Hospital, Tokyo, Japan.
Cancer Sci ; 109(5): 1552-1561, 2018 May.
Article em En | MEDLINE | ID: mdl-29478257
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Bortezomib / Mieloma Múltiplo Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Bortezomib / Mieloma Múltiplo Idioma: En Ano de publicação: 2018 Tipo de documento: Article